美國居民不適用 XM 服務。

1 drugs compound snack makers' woes



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>LIVE MARKETS-GLP-1 drugs compound snack makers' woes</title></head><body>

Major U.S. indexes modestly red; Dow off ~0.4%

Cons disc weakest S&P sector; Energy leads gainers

Euro STOXX 600 index up ~0.2%

Dollar ~flat; gold slips; crude, bitcoin both up >2

U.S. 10-Year Treasury yield rises to ~4.03%

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

GLP-1 DRUGS COMPOUND SNACK MAKERS' WOES

Packaged food makers such as Hershey HSY.N face a greater threat from weight-loss drugs than anticipated, with usage on the rise, helped by online health platforms offering compounded GLP-1 weight-loss injections, analysts at Bernstein noted.

With branded GLP-1 drugs from Novo Nordisk and Eli Lilly short in supply, demand for custom-made weight-loss treatments created by combining, mixing, or altering drug ingredients has soared, and could be reaching a larger number of GLP-1 patients than captured in official data, Bernstein said.

Patterns of food consumption pointed to weakness for sweet snacks and fast food, and strength for healthier items such as soup, cottage cheese and Greek yogurt, which are consistent with the eating habits of GLP-1 patients, Bernstein noted.

The brokerage downgraded chocolate maker Hershey to "market-perform," on risks that volume recovery may be more sluggish than expected due to GLP-1 headwinds, while raising soup maker Campbell to "outperform."

U.S. telehealth company Hims & Hers Health HIMS.N began selling compounded GLP-1 medications in May. The company said in August, that the program had about 100,000 subscribers.

Vitamin Shoppe also provided access to weight-loss medication through its telehealth service, while retailer Costco Wholesale offered its roughly 130 million members access to weight-loss programs this year.

The S&P 500 Packaged Foods & Meats .SPLRCFOOD has risen 2.6% so far this year, lagging a 14% rise in the consumer staples index .SPLRCS, and a 20% rise in the S&P 500 .SPX index.


(Juveria Tabassum)

*****



FOR MONDAY'S EARLIER LIVE MARKETS POSTS:


PAYROLLS HANGOVER: GEOPOLITICS, UNCERTAINTIES WEIGH ON RISK APPETITE - CLICK HERE


CRUDE OIL FUTURES HEATING UP ON THE CHARTS - CLICK HERE


U.S. ELECTION: PREPARE FOR UNCERTAINTY AND VOLATILITY - CLICK HERE


REAL ESTATE TOUR: WARMING UP TO OFFICES - CLICK HERE


RISING YIELDS WEIGH, BANKS EDGE UP - CLICK HERE


EUROPEAN FUTURES INCH HIGHER - CLICK HERE


US 'NO LANDING' SCENARIO LIFTS MARKETS - CLICK HERE



</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明